Loki Therapeutics is a pre-clinical stage immune oncology company, focus on treating advanced ovarian and pancreatic cancers. Our innovative approach combines an attenuated Listeria delivery system with childhood vaccine antigen payload. This allows us to bypass the traditional approach of training naive t-cells and instead we redirect a strong memory t-cell response to the tumor and metastases with very promising pre clinical results.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Oncology
Lead Product in Development:
AWAKE-101
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
